Puma Biotechnology Inc (PBYI)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Alan H. Auerbach
Employees:
200
10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES, CA 90024
(424) 248-6500

Puma Biotechnology, Inc. focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd.

Data derived from most recent annual or quarterly report
Market Cap 164.152 Million Shares Outstanding44.973 Million Avg 30-day Volume 267.601 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0.28
Price to Revenue1.8038 Debt to Equity-16.5201 EBITDA-36.198 Million
Price to Book Value0.0 Operating Margin-13.505400000000002 Enterprise Value398.812 Million
Current Ratio1.279 EPS Growth0 Quick Ratio1.041
1 Yr BETA 1.2195 52-week High/Low 7.84 / 1.6 Profit Margin-26.6514
Operating Cash Flow Growth-96.5454 Altman Z-Score-6.2404 Free Cash Flow to Firm -20.483 Million
Earnings Report2022-11-03
View SEC Filings from PBYI instead.

View recent insider trading info

Funds Holding PBYI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PBYI

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-06-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-03-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-10:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-14:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-11-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    147.2 Thousand total shares from 13 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    AUERBACH ALAN H PRESIDENT AND CEO

    • Officer
    • Director
    • 10% Owner
    6,316,705 2022-08-02 13

    HUNT DOUGLAS M SEE REMARKS

    • Officer
    77,301 2022-08-02 13

    NOUGUES MAXIMO F CHIEF FINANCIAL OFFICER

    • Officer
    111,577 2022-08-02 16

    CESANO ALESSANDRA

    • Director
    0 2022-07-29 2

    LUDWIG JEFFREY JEROME CHIEF COMMERCIAL OFFICER

    • Officer
    64,625 2022-07-05 3

    WONG ALVIN F CHIEF SCIENTIFIC OFFICER

    • Officer
    58,527 2022-07-05 4

    MOYES JAY M

    • Director
    38,322 2022-06-16 2

    WILSON TROY EDWARD

    • Director
    27,900 2022-06-16 2

    SENDEROWICZ ADRIAN

    • Director
    27,000 2022-06-16 2

    STUGLIK BRIAN M

    • Director
    41,858 2022-06-16 2

    MILLER MICHAEL PATRICK

    • Director
    79,858 2022-06-14 2

    DORVAL ALLISON

    • Director
    27,000 2022-06-14 1

    MILLER ANN CALBY

    • Director
    40,732 2021-06-15 0

    BRYCE RICHARD PAUL SEE REMARKS

    • Officer
    121,662 2021-04-05 0

    ZAVRL FRANK

    • Director
    960,069 2020-06-09 0

    O'DOWD HUGH

    • Director
    25,748 2020-06-09 0

    LO STEVEN CHIEF COMMERCIAL OFFICER

    • Officer
    19,557 2019-07-22 0

    EYLER CHARLES R SEE REMARKS

    • Officer
    31,957 2019-02-04 0

    ADAGE CAPITAL PARTNERS GP, L.L.C.

    ADAGE CAPITAL PARTNERS, L.P.

    ADAGE CAPITAL ADVISORS, L.L.C.

    ATCHINSON ROBERT

    GROSS PHILLIP

    • 10% Owner
    No longer subject to file 2017-06-08 0

    CHARNAS ROBERT SEE REMARKS

    • Officer
    0 2017-02-16 0

    PHILLIPS RICHARD BENTON SEE REMARKS

    • Officer
    0 2016-04-15 0

    MALLEY THOMAS

    • Director
    0 2014-12-15 0

    JOHNSON ROBERT ANDREW

    • FORMER PRESIDENT AND DIRECTOR
    No longer subject to file 2011-10-04 0

    MUNJAL KAPIL

    • FORMER DIRECTOR
    No longer subject to file 2011-10-04 0

    SIDDIQI FARAAZ

    • FORMER SECRETARY AND DIRECTOR
    No longer subject to file 2011-10-04 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    NOUGUES MAXIMO F - Officer CHIEF FINANCIAL OFFICER

    2022-08-04 21:34:38 -0400 2022-08-02 S 161 $2.89 d 111,577 direct -9.1146 0.0 1 -9.1146 2

    HUNT DOUGLAS M - Officer SEE REMARKS

    2022-08-04 18:48:43 -0400 2022-08-02 S 429 $2.89 d 77,301 direct -9.1146 0.0 1 -9.1146 2

    AUERBACH ALAN H - Director - Officer - > 10% Owner PRESIDENT AND CEO

    2022-08-04 18:42:16 -0400 2022-08-02 S 1,247 $2.89 d 6,316,705 direct -9.1146 0.0 1 -9.1146 2

    CESANO ALESSANDRA - Director

    2022-08-02 17:07:16 -0400 2022-07-29 A 100,000 a 100,000 direct

    WONG ALVIN F - Officer CHIEF SCIENTIFIC OFFICER

    2022-07-07 20:15:02 -0400 2022-07-05 S 2,920 $2.63 d 58,527 direct -4.7782 7.5085 8.8737 5 -4.7782 2

    NOUGUES MAXIMO F - Officer CHIEF FINANCIAL OFFICER

    2022-08-04 21:30:44 -0400 2022-07-05 S 9,328 $2.63 d 111,738 direct -9.1146 0.0 1 -9.1146 2

    HUNT DOUGLAS M - Officer SEE REMARKS

    2022-07-07 20:41:29 -0400 2022-07-05 S 3,753 $2.63 d 77,730 direct -4.7782 7.5085 8.8737 5 -4.7782 2

    AUERBACH ALAN H - Director - Officer - > 10% Owner PRESIDENT AND CEO

    2022-07-07 20:21:19 -0400 2022-07-05 S 26,140 $2.63 d 6,317,952 direct -4.7782 7.5085 8.8737 5 -4.7782 2

    NOUGUES MAXIMO F - Officer CHIEF FINANCIAL OFFICER

    2022-07-07 20:19:05 -0400 2022-07-05 S 5,835 $2.63 d 64,625 direct -4.7782 7.5085 8.8737 5 -4.7782 2

    LUDWIG JEFFREY JEROME - Officer CHIEF COMMERCIAL OFFICER

    2022-07-07 20:17:14 -0400 2022-07-05 S 5,835 $2.63 d 64,625 direct -4.7782 7.5085 8.8737 5 -4.7782 2

    SENDEROWICZ ADRIAN - Director

    2022-06-21 21:55:01 -0400 2022-06-16 S 27,858 $2.63 d 27,000 direct yes -0.6849 -2.3973 11.9863 13.0137 19 -8.9041 9

    WILSON TROY EDWARD - Director

    2022-06-21 19:12:17 -0400 2022-06-16 S 27,858 $2.58 d 27,350 direct yes -0.6849 -2.3973 11.9863 13.0137 19 -8.9041 9

    STUGLIK BRIAN M - Director

    2022-06-21 19:09:13 -0400 2022-06-16 S 13,000 $2.69 d 41,858 direct yes -0.6849 -2.3973 11.9863 13.0137 19 -8.9041 9

    MOYES JAY M - Director

    2022-06-21 19:05:16 -0400 2022-06-16 S 22,858 $2.64 d 38,322 direct yes -0.6849 -2.3973 11.9863 13.0137 19 -8.9041 9

    WILSON TROY EDWARD - Director

    2022-06-16 18:49:49 -0400 2022-06-14 A 27,000 a 55,208 direct 3.7453 8.2397 10.4869 23.5955 21 -0.3745 11

    SENDEROWICZ ADRIAN - Director

    2022-06-17 16:26:56 -0400 2022-06-14 A 27,000 a 54,858 direct 5.4152 0.361 12.2744 19.1336 20 -3.9711 10

    MOYES JAY M - Director

    2022-06-17 16:22:39 -0400 2022-06-14 A 27,000 a 61,180 direct 5.4152 0.361 12.2744 19.1336 20 -3.9711 10

    DORVAL ALLISON - Director

    2022-06-17 16:16:18 -0400 2022-06-14 A 27,000 a 27,000 direct 5.4152 0.361 12.2744 19.1336 20 -3.9711 10

    STUGLIK BRIAN M - Director

    2022-06-16 20:04:01 -0400 2022-06-14 A 27,000 a 54,858 direct 3.7453 8.2397 10.4869 23.5955 21 -0.3745 11

    MILLER MICHAEL PATRICK - Director

    2022-06-16 18:56:23 -0400 2022-06-14 A 27,000 a 79,858 direct 3.7453 8.2397 10.4869 23.5955 21 -0.3745 11

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 21:15:05 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 20:45:04 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 20:15:06 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 19:45:04 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 19:15:05 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 18:45:04 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 18:15:04 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 17:45:04 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 17:15:04 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 16:45:04 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 16:15:03 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 15:45:05 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 15:15:05 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 14:45:04 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 14:15:03 UTC 1.8902 0.4298 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 13:45:03 UTC 1.9115 0.4085 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 13:15:04 UTC 1.9115 0.4085 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-10 12:45:05 UTC 1.9115 0.4085 850000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-09 22:15:07 UTC 1.9115 0.4085 650000
    PUMA BIOTECHNOLOGY INC PBYI 2022-08-09 21:45:04 UTC 1.9115 0.4085 650000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments